ACAD
アカディア・ファーマシューティカルズ
ACAD
アカディア・ファーマシューティカルズ
ACADIA Pharmaceuticals Inc. (ACAD) Discusses Top-Line Phase II Results From RADIANT Study of Remlifanserin in Alzheimer's Disease Psychosis Transcript
Acadia Pharmaceuticals (ACAD) reported phase 2/3 results for remlifanserin in Alzheimer's disease psychosis, with the high dose missing statistical significance but showing positive efficacy trends. R